ANTI-EPCAM ANTIBODY FRAGMENT-BOUGANIN FUSION PROTEIN
Neoplasms, Glandular and Epithelial
Sesen Bio, Inc.protein_peptidePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
25 Active assets in the Neoplasms, Glandular and Epithelial cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Sorafenib Shandong Cancer Hospital and Institute | Phase 3 | BB |
Catumaxomab Neovii Biotech | Phase 2/3 | B |
Pembrolizumab Sheba Medical Center | Phase 2 | B |
Enadenotucirev Akamis Bio | Phase 1/2 | B |
Linifanib Abbott | Phase 3 | B |
View all 36 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →